Introduction
There are multiple signal transduction pathways resulting in apoptosis, and many extracellular and intracellular factors have been characterized as triggers for this process (Strasser, 1999) . The resistance of transformed cells to apoptosis contributes to the development of cancers. Current strategies for management of those diseases act in part by inducing program cell death (Sellers and Fisher, 1999) . In colorectal cancers, a direct correlation between increased levels of apoptosis and tumor regression after radio-or chemotherapy has been shown (Scott et al., 1998; Farczadi et al., 1999) . Understanding the molecular mechanisms that result in apoptosis of cancer cells may contribute to the development of new therapeutic approaches. Here we describe studies that were undertaken to elucidate the molecular basis for the enhanced activity observed when two apoptosis-inducing agents, Apo2L/TRAIL and CPT-11, are used in combination in vitro and in vivo (Walczak et al., 1999; Gliniak and Le, 1999) .
Apo2L/TRAIL is a type II transmembrane homotrimer (60 kDa) (Wiley et al., 1995; Pitti et al., 1996) belonging to the TNF cytokine family, which includes TNF-alpha and Fas ligand. Apo2L/TRAIL binding to functional receptors results in selective, p53-independent apoptosis of tumor cells (Wiley et al., 1995; Pitti et al., 1996; Rieger et al., 1998) . Apo2L/TRAIL interacts speci®cally with ®ve dierent receptors Ashkenazi and Dixit, 1999) : DR4, DR5, DcR1, DcR2, and OPG. DR4 and DR5 are type I transmembrane proteins that contain conserved cytoplasmic death domains responsible for recruiting adapter proteins such as FADD to the receptor complex, resulting in tumor apoptosis. DcR1 is a glycosylphosphatidylinositol-linked protein, and DcR2 is a type I membrane protein with an incomplete cytoplasmic death domain. Consequently, binding of Apo2L/TRAIL to these decoy receptors does not activate the apoptotic machinery.
Camptothecin (CPT) and all of its analogs are potent DNA topoisomerase I (topl) inhibitors. Irinotecan (CPT-11) is a CPT prodrug derivative with enhanced water solubility. CPT-11 is currently used as ®rst and second-line therapy in the treatment of patients with advanced colorectal cancer.
Exposure to DNA-damaging agents (Lu and Lane, 1993) , including camptothecin (Tishler et al., 1993) , increases the protein levels of the tumor suppressor gene p53. p53 activation mediates tumor suppression by regulation of gene expression and also through transcriptionally independent pathways resulting either in apoptosis and/or cell cycle arrest. The induction of p21 by p53 plays a central role in cell cycle arrest. p21 is a potent inhibitor of cyclin-dependent kinase (CDK) activities that control cell cycle progression (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) . Selective p53-dependent upregulation of DR5 (Wu et al., 1997 (Wu et al., , 1999 has been observed in a number of tumor cell lines exposed to dierent anti-cancer genotoxic-stress chemicals such as doxorubicin, etoposide or following gamma irradiation. Upregulation of DR5 in a p53-independent fashion has also been demonstrated by treatment of tumor cells with TNF (Sheikh et al., 1998) or by several chemotherapeutic agents in dierent human glioma cell lines (Nagane et al., 2000) . Furthermore, upregulation of DR5 correlated in most cases with increased responsiveness to caspase-dependent Apo2L/TRAIL-mediated apoptosis (Chinnaiyan et al., 2000) . In the current study we have investigated several factors that may account for the enhanced apoptotic activity observed when Apo2L/ TRAIL plus CPT-11 are used in combination or sequentially. The modulation of Apo2L/TRAIL death receptors by CPT-11 and Apo2L/TRAIL as well as the opposing eect of these agents on p21 levels were characterized.
Results

Apoptotic profile in vitro
A quantitative analysis of cell survival (Figure 1) showed sensitization of HCT116 cells to Apo2L/ TRIAL-mediated apoptosis by both CPT-11 and SN-38. At 24 h, the co-treatment of Apo2L/TRAIL and CPT-11 or SN-38 (combination treatment) resulted in a 32 and 42% increase in cytotoxicity, respectively, in comparison to Apo2L/TRAIL alone. These results were consistent with morphological changes and survival data assessed in the presence of the¯uorescent dyes calcein-AM and ethidium homodimer-1 (data not shown).
Caspase-3 activation
Apo2L/TRAIL-induced apoptosis requires caspase-3 activation . Following exposure of HCT116 cells to Apo2L/TRAIL or CPT-11 or the combination of these agents, caspase-3 activation was assessed by Western blot and¯uorometric analysis as described in Materials and methods. Western blot analysis showed that after 2 h of treatment, both Apo2L/TRAIL and the combination treatment induced signi®cant cleavage of caspase-3 into its p24, p20, and p17 forms (Figure 2 ). Caspase 3 activation was con®rmed independently by a¯uorometric assay. At 24 h, the combination treatment caused a clear increase in caspase-3 processing and activity in comparison with Apo2L/TRAIL or CPT-11 alone. Furthermore, a variation of the combination treatment in which the cells were incubated overnight with CPT-11 alone, followed by 2 h of treatment with Apo2L/TRAIL (sequential) in addition to CPT-11, resulted in the highest degree of caspase-3 cleavage and activity. Taken together, these results show an enhancement in caspase-3 activation after combined Apo2L/ TRAIL+CPT-11 treatment that leads to increased tumor apoptosis.
Regulation of Apo2L/TRAIL and its receptors
The eects of Apo2L/TRAIL and CPT-11 on the expression of Apo2L/TRAIL death receptors DR5 and DR4 were distinct, as measured by a bDNA TM assay. Apo2L/TRAIL induced a twofold transient increase in DR5 mRNA expression after 2 h of treatment and returned to control levels after 24 h (Figure 3 ). This agent did not aect DR4 mRNA. In contrast, CPT-11 resulted in a 2.2-fold increase in both DR4 and DR5 mRNA at 24 h but no eect was observed after 2 h of treatment. Sequential treatment resulted in the highest upregulation of DR4 and DR5 expression (threefold). Similar results (data not shown) were obtained when experiments were conducted in the presence of a general caspase inhibitor, Z-VAD, to analyse the entire cell population rather than the surviving cells at 24 h. Real time RT ± PCR analysis (Taqman TM ) data con®rmed the bDNA death receptor regulation results (data not Figure 5 showed that the expression of Apo2L/TRAIL ligand itself was transiently induced (6 h) by all treatments. The sequential group resulted in the highest Apo2L/TRAIL induction (3.5-fold).
Role of p21 in apoptosis versus cell cycle arrest
We examined whether p53 and its downstream target p21 are involved in mediating the dierent responses observed after treating tumor (HCT116) and normal (HUVEC) cells with Apo2L/TRAIL and CPT-11 alone or in combination. Aliquots were analysed in parallel for p21 and p53 protein levels by Western blot. Apo2L/TRAIL alone did not change p53 or p21 expression in either HCT116 cells or HUVECs ( Figure  6 ). In contrast, CPT-11 alone strongly induced p53 and p21 protein at 24 h in both tumor and normal cells. The combination treatment of normal cells by Apo2L/ TRAIL+CPT-11 resulted in increased p53 and p21 expression similar to observed with CPT-11 alone. Surprisingly, although p53 was greatly increased after combination treatment of HCT116 tumor cells, levels of p21 protein remained at baseline. Similar responses were observed when CPT-11 was substituted by its metabolite SN-38 (data not shown). These data provided evidence that in HCT116 tumor cells, but not in normal HUVECs, Apo2L/TRAIL prevents the increase in p21 protein levels associated with the induction in p53 after CPT-11 or SN-38 treatment.
Cell cycle analysis
To determine if a direct correlation exists between p21 induction and changes in the cell cycle pro®le of treated cells and in particular, the appearance of cell cycle arrest, treated and control HCT116 cells were subjected to cell cycle analysis. At 6 h ( Figure 7 ), 30% of control cells were found in G 0 -G 1 . CPT-11 alone induced a signi®cant shift in the cell cycle pro®le resulting in a G 0 -G 1 cell cycle arrest (76%). This shift was also present, albeit to a lesser degree, in the combination Apo2L/TRAIL+CPT-11 treatment (55%) and was not signi®cantly induced by Apo2L/ TRAIL alone (43%). By 24 h, CPT-11 treatment resulted in an entirely dierent pro®le characterized by the appearance of a G 2 -M phase arrest (42% vs 19% control) and a clear reduction in G 0 -G 1 phase. More importantly, the combination of Apo2L/ Figure 2 Maximal activation of caspase-3 is observed following sequential treatment of HCT116 cells with CPT-11 followed by Apo2L/TRAIL. HCT116 cells were treated for 2 and 24 h with Apo2L/TRAIL (1 mg/ml), CPT-11 (50 mg/ml), and Apo2L/ TRAIL+CPT-11 at the same concentrations. In the sequential treatment, cells were exposed for the initial 22 h to CPT-11, then Apo2L/TRAIL was added for an additional 2 h of incubation. Equivalent aliquots of cell lysates were assessed for pro-caspase-3 processing by Western blot analysis and for caspase-3 activity by¯uorometric assay (see Materials and methods) TRAIL+CPT-11 completely prevented the appearance of this G 2 -M arrest (17% vs 19% control) after 24 h of treatment. These data are consistent with the Apo2L/ TRAIL-mediated suppression of CPT-11 induction of p21. Cell cycle analysis of normal cells for 24 h under similar experimental conditions showed no dierences among the treatments (data not shown).
Cell cycle analyses also provided con®rmation of the increased apoptotic activity of the combination Apo2L/ TRAIL+CPT-11 treatment, by detection of apoptotic cells as de®ned by subdiploid DNA content (sub G1). Apo2L/TRAIL+CPT-11 (24 h) resulted in apoptosis of 42% of cells vs 19% apoptosis with Apo2L/TRAIL alone and 9% apoptosis with CPT-11 treatment. Only 1% of control cells were found to be in subG1 ( Figure  7 ). These results further support the concept that the combined Apo2L/TRAIL+CPT-11 treatment mediates tumor suppression by preventing p21 accumulation and directing the cancer cells towards the apoptotic, rather than the cell cycle arrest pathway.
Role of caspase activation in the regulation of p21 protein levels by Recent studies have indicated opposite roles for p21 in the apoptotic process, either as a caspase substrate (Zhang et al., 1999a; Levkau et al., 1998; Gervais et al., 1998) or as an inhibitor of caspase activation (Suzuki et al., 1998 (Suzuki et al., , 1999a (Suzuki et al., ,b, 2000 . To determine the role of caspase activation by Apo2L/TRAIL in the regulation of p21 protein levels, HCT116 cells were treated as previously described and also in the presence of the general caspase inhibitor, Z-VAD. Caspase inhibition resulted in a noticeable increase in the cellular levels of p21 in the combination Apo2L/TRAIL+CPT-11 group as compared to the same treatment without Z-VAD Figure 3 Treatment of HCT116 cells with Apo2L/TRAIL and CPT-11 alone or in combination results in distinct changes in DR5 and DR4 gene expression. DR5 and DR4 mRNA levels were determined by bDNA TM assay following incubation with Apo2L/TRAIL (1 mg/ml), CPT-11 (50 mg/ml), Apo2L/TRAIL+ CPT-11 for 2, 6 and 24 h, respectively. In the sequential treatment, cells were exposed for the initial 22 h to CPT-11, then Apo2L/TRAIL was added for an additional 2 h of incubation. Controls were shown in open circle. mRNA was puri®ed as described in Materials and methods. Relative values were calculated as ratios to GAPDH and normalized to untreated control cultures (mean+s.d. n=3) Figure 4 Treatment of HCT116 cells with Apo2L/TRAIL and SN-38 alone or in combination results in distinct changes in DcR1 and DcR2 mRNA expression pro®les. DcR1 and DcR2 mRNA levels were determined by Taqman following incubation with Apo2L/TRAIL (1 mg/ml) or SN-38 (125 ng/ml) alone and in combination or sequentially for 24 h. In the sequential treatment, cells were exposed for the initial 24 h to CPT-11, then Apo2L/ TRAIL was added for an additional 2 h of incubation. Controls were shown in open circle. mRNA was puri®ed as described in Materials and methods. Relative values were normalized to untreated control cultures (n=2) (Figure 8 ). Major dierences were not observed with the remaining treatment groups. When tumor cells were pre-incubated with CPT-11 overnight and then treated for 2 h with Apo2L/TRAIL before analysis, there was a similar decrease in p21 levels as detected in the combination treatment for 24 h. Degradation of p21 was con®rmed by the presence of a cleaved fragment at approximately 15 kDa under these conditions. This experiment demonstrated that inhibition of caspase activity prevented the otherwise strong degradation of p21 induced by Apo2L/TRAIL. To further assess the possibility of a functional correlation between caspase activation, levels of p21 and cell cycle arrest, cell cycle analysis was performed and showed that Apo2L/ TRAIL did not prevent the CPT-11-induced G 2 -M arrest in the presence of the caspase inhibitor Z-VAD (data not shown).
Sequential treatment further enhances tumor apoptosis
To determine the most eective combination regimen for Apo2L/TRAIL and CPT-11 in vitro, we compared two dierent conditions of the combination treatment. In the ®rst condition (combination), tumor cells were exposed to Apo2L/TRAIL and CPT-11 for a total of 24 h, followed for another 24 h incubation in the presence of medium alone. In the second group (sequential), cells were exposed for the initial 24 h to CPT-11, then changed to Apo2L/TRAIL alone containing medium for another 24 h. Figure 9a shows that the total cell killing in the sequential treatment was enhanced around 6% more than the combination group (P50.001, t-test). Moreover, the relative killing activity comparing the sequential and combination treatments increased as much as 54%. This eect was seen at dierent concentrations of Apo2L/TRIAL. Furthermore, the relative increased apoptotic eect of the sequential over the combination treatment was enhanced as much as 68% when the cells were incubated for an additional 4 days in drug free medium following 2 days of drug exposure (Figure 9b ). Survival analysis comparing combination versus sequential treatment using SN-38 instead of CPT-11 showed a similar overall eect (Figure 9c ).
Discussion
We have investigated the possible molecular mechanisms by which Apo2L/TRAIL and CPT-11, two agents that induce apoptosis in tumor cells by distinct pathways, mediate enhanced activity together.
First, the possibility that the co-treatment eect was due to changes in the metabolism of CPT-11 as a result of Apo2L/TRAIL treatment was ruled out. Similar results were obtained using the active metabolite SN-38 instead of the parent molecule. Second, the enhanced activity observed in combination treatment did not require extraordinary concentrations of CPT-11. This eect was observed in these studies with concentrations of CPT-11 and SN-38 consistent with plasma concentrations reported for preclinical and clinical studies (Rothenberg et al., 1993; Sparreboom et al., 1998; Choi et al., 1998) .
Other workers have reported that ionizing radiation (Chinnaiyan et al., 2000) , ectoposide (Nagane et al., Figure 5 Apo2L/TRAIL induction is observed in HCT116 cells following treatment with Apo2L/TRAIL and SN-38 alone or in combination. Apo2L/TRAIL mRNA levels were determined by Taqman following incubation with Apo2L/TRAIL (1 mg/ml), SN-38 (125 ng/ml), Apo2L/TRAIL+SN-38 for 24 h. mRNA was puri®ed as described in Materials and methods. Relative values were normalized to untreated control cultures Figure 6 Apo2L/TRAIL treatment suppresses CPT-11-mediated induction of p21 protein levels in tumor but not in HUVEC cells. Colon human HCT116 tumor and normal HUVEC cells were treated for 2 and 24 h with Apo2L/TRAIL (1 mg/ml), CPT-11 (50 mg/ml), and Apo2L/TRAIL+CPT-11. Equivalent aliquots of cell lysates (50 mg/lane) were tested for p21 protein expression by Western blot analysis Oncogene Apo2L/TRAIL and CPT-11 enhanced tumor apoptosis H Xiang et al 2000; Gibson et al., 2000) , or CDDP (Nagane et al., 2000) sensitize tumor cells to Apo2L/TRAIL-mediated apoptosis by upregulating the Apo2L/TRAIL receptor DR5. We therefore evaluated the eects of Apo2L/ TRAIL and CPT-11, alone and in combination, on Apo2L/TRAIL receptors and Apo2L/TRAIL expression.
The treatment of Apo2L/TRAIL responsive tumor cells with Apo2L/TRAIL induced a transient increase in DR5 receptors only. In contrast, CPT-11 exposure resulted in upregulation not only of DR5, as expected from a DNA damaging agent, but the induction of DR4 was also observed. Furthermore, CPT-11 treatment resulted in a moderate upregulation of Apo2L/TRAIL and a strong induction of its two decoy receptors, DcR1 and DcR2, while both combination and sequential treatment with CPT-11 and Apo2L/TRAIL decreased the expression of the decoy receptors. The sequential treatment of CPT-11 followed by Apo2L/TRAIL resulted in the greatest increases of Apo2L/TRAIL, DR5 and DR4. The induction of these pro-apoptotic genes combined with the down-regulation of decoy receptors is consistent with the observed increase in tumor killing and may play an important role in the overall modulation of the apoptotic response.
Apoptosis is the principal mechanism in the cellular killing mediated by DNA-damaging anti-cancer drugs and p53 is considered to play a central role in this process. However, p53 may also act as a tumor suppressor by inducing growth arrest, through upregulation of p21. It has been previously described that CPT analogs induce transient cell cycle arrest either at the G 1 or G 2 phases in cancer cells (Deptala et al., 1999; McDonald and Brown, 1998) . Here we have shown a dramatic inhibition of p21 induction upon CPT-11 Figure 7 Apo2L/TRAIL suppresses CPT-11 induced G 2 /M cell cycle arrest. HCT116 tumor cells were treated for 2, 6 and 24 h with Apo2L/TRAIL (1 mg/ml), CPT-11 (50 mg/ml), and Apo2L/TRAIL+CPT-11. Following treatment, the cell cultures were processed by¯ow cytometric cell cycle analysis (see Materials and methods for details) Figure 8 The caspase inhibitor Z-VAD (I) has a dierential eect on the levels of p53 and p21. Cell cultures were treated as previously described with or without 20 mM of Z-VAD-FMK for 24 h. Cell lysates were processed for Western blot analysis of p53 and p21 protein levels Apo2L/TRAIL and CPT-11 enhanced tumor apoptosis H Xiang et al treatment when given in combination with Apo2L/ TRAIL. The presence of Apo2L/TRAIL also prevented the altered cell cycle pro®le, characterized by a noticeable increase in the percentage of cells at the G 2 -M phase, observed with tumor cells treated with CPT-11 alone. Instead, the Apo2L/TRAIL+CPT-11 combination treatment resulted in increased tumor apoptosis. Regardless of the mechanisms by which Apo2L/TRAIL treatment prevents p21 accumulation and growth arrest by CPT-11, it is clear that the combined treatment forced the carcinoma cells towards an apoptotic pathway rather than cell cycle arrest and possible DNA repair. This is in clear agreement with the enhanced antitumor activity shown in vivo with the combination treatment Gliniak and Le, 1999) . We have further demonstrated that the mechanism by which Apo2L/TRAIL prevents the CPT-11 mediated accumulation of p21 requires caspase activation. It has been established that caspase-mediated cleavage inactivation of p21 is a necessary step in the apoptotic death of human lung and colorectal cancer cells (Zhang et al., 1999b; Chai et al., 2000) . Under these conditions, p21 expression will work not only as a cell cycle regulator but also more importantly, as recently shown, as a survival agent that directly antagonizes apoptosis (Xu and El-Deiry, 2000; Javelaud et al., 2000; Burgess et al., 2001; Mahyar-Roemer and Roemer, 2001) . Consistent with these reports, the presence of the general caspase inhibitor, Z-VAD, eectively blocks Apo2L/TRAIL-mediated apoptosis, induced degradation of p21, as well as the Apo2L/ TRAIL-dependent prevention of the G 2 -M phase cell arrest mediated by CPT-11.
In conclusion, we have identi®ed mechanisms in vitro by which CPT-11 and Apo2L/TRAIL, two agents that mediate apoptosis through distinct pathways, DNA damage and death signaling receptors, respectively, can act in concert. Namely, upregulation of the pro-apoptotic genes Apo2L/TRAIL and its two death receptors DR5 and DR4, as well as Apo2L/ TRAIL inhibition of decoy receptors and p21-induction by CPT-11, results in enhanced apoptosis. A further increase in apoptotic death was demon- Figure 9 Sequential treatment enhances total cell killing in tumor cells. (a) In the combination group, HCT116 cells were exposed to CPT-11 (10 mg/ml) and dierent concentrations of Apo2L/TRAIL (as indicated in the ®gure) for a total of 24 h, followed by another 24 h of incubation in the presence of medium alone. In the sequential group, cells were exposed for the initial 24 h to CPT-11, then changed to Apo2L/TRAIL containing medium for another 24 h. Cell survival was determined by crystal violet assay as described in Materials and methods (mean+s.d. n=4). (b) HCT116 cells (combination) were exposed to CPT-11 (10 mg/ml) and dierent concentrations of Apo2L/TRAIL for a total of 24 h, followed by another 120 h of incubation in the presence of medium alone. In the sequential group, cells were exposed for the initial 24 h to CPT-11, then changed to Apo2L/ TRAIL containing medium for another 24 h followed by incubation of drug free medium for 96 h and tested for cell survival as before. (c) HCT116 cells (combination) were exposed to SN38 (50 ng/ml) and 20 or 200 ng/ml of Apo2L/TRAIL for a total of 24 h, followed by another 24 h of incubation in the presence of medium alone. In the sequential group, cells were exposed for the initial 24 h to SN-38, then changed to Apo2L/ TRAIL containing medium for another 24 h followed by incubation of drug free medium for 24 h and tested for cell survival as before AlamarBlue assay was used to determine cell survival. Concentrations of CPT-11 and SN-38 were 50 mg/ml and 125 ng/ml, respectively. Apo2L/TRAIL ranged from 5 ng/ml to 1 mg/ml depending on cell lines strated where tumor cells are pretreated with CPT-11 for 24 h followed by Apo2L/TRAIL. The enhanced apoptosis by the combination treatment was not con®ned to HCT116 cells and has been shown on every Apo2L/TRAIL responsive colon carcinoma cell line tested in vitro (Table 1) . Additional studies are planned to investigate regulation of p21 and death receptors by Apo2L/TRAIL and CPT-11 in vivo and to further assess the applicability of these observations to other tumor types.
Materials and methods
Cell culture
Human colon carcinoma cell lines HCT116, COLO205, LoVo and SW48 were obtained from the American Type Culture Collection (Manassas, VA, USA). Human umbilical vein endothelial cells (HUVEC) were obtained from Cell Systems (#2V0-C75; Kirkland, WA, USA) and incubated in CS-C TM complete medium (#4Z0-500; Cell Systems).
Drugs and Chemicals
Apo2L/TRAIL was constructed, expressed and puri®ed at Genentech, Inc. CPT-11 was purchased from Pharmacia & Upjohn Company, Kalamazoo, MI, USA. Z-VAD-FMK (Enzyme Systems, Livermore, CA, USA) was used at a ®nal concentration of 20 mM. SN-38 was a gift from Dr Jacques Gaudreault (Genentech, South San Francisco, CA, USA).
Cell viability
Two dierent procedures were used in these studies. AlamarBlue TM (AccuMed International, Inc., Chicago, IL, USA) assay was used to determine the cell viability. AlamarBlue TM was added to the wells for the last 6 h of the 24 h incubation time. Fluorescence was read using a 96-well¯uorometer plate reader with an excitation of 530 nm and emission of 590 nm (CytoFluor multi-well plate reader series 4000; PerSeptive Biosystems, Framingham, MA, USA).
Crystal violet assay was also used. At the end of each treatment, the medium was removed and 100 ml of 0.5% crystal violet solution was added to each well and incubated at room temperature for 10 min before being washed with water. After the wells were dry, 100 ml of ethanol containing 0.5 N HCL was added to each well. The plates were read at 540 nm using a 96-well plate reader (Spectra Max 340pc; Molecular Devices Corporation, Sunnyvale, CA, USA).
Caspase-3 activity
Caspase activity was determined by caspase-3 assay kit (Clontech, Palo Alto, CA, USA). The assay was performed according to the manufacturer's instruction. After treatment, cells were collected. The cell lysates were incubated with the¯uorogenic caspase substrate (DEVD-AFC, 50 mM) in reaction buer at 378C for 1 h. The samples were analysed in a CytoFluor multi-well plate reader (PerSeptive Biosystems) with a 400/30 nm excitation ®lter and a 508/ 20 nm emission ®lter. The levels of relative¯uorescence were normalized against the protein concentration of each sample.
Total RNA isolation
Total RNA was isolated using the RNA Stat-60 TM solution (Tel-Test, Inc., Friendsweed, TX, USA) according to the manufacturer's instruction. Quantigene bDNA TM signal ampli®cation assay (Chiron Diagnostics, East Walpole, MA, USA) was used to evaluate mRNA levels. The speci®city of the DR4 and DR4 probes was tested using RNA from in vitro transcription using recombinant DcR1, DcR2, DR4 and DR5 constructs. Both DR4 and DR5 probe sets were highly speci®c for their own RNA transcripts. The signal from each probe sets was linear with the concentrations tested. bDNA TM assays were performed according to the manufacturer's instructions using about 2 mg of total RNA/well. For Taqman, the total RNA was puri®ed by Qiagen RNeasy Mini kit (Qiagen, Santa Clarita, CA, USA). Prior to addition to the RNeasy column, samples were homogenized with the Qiagen QlAshredder (Qiagen, Santa Clarita, CA, USA). RNA Concentration was determined with RiboGreen RNA Quantitation Reagent (Molecular Probes, Eugene, OR, USA). Primer express (PE applied biosystems, Foster City, CA, USA) was used to design all the primers and probes. Expression of analysis of each gene of interest was achieved with two-step real time RT ± PCR using the ABI 7700 Sequence Detection System (PE applied biosystems, Foster City, CA, USA).
Western blot
Cell lysates aliquots of 50 mg of total protein per well were separated in a NuPAGE 4 ± 12% Bis-Tris gel (Novex, San Diego, CA, USA). The gels were transferred to 0.2 mM pure nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membranes were incubated with primary antibodies followed by a horseradish peroxide-coupled secondary antibody (Amersham, Braunschweig, Germany). Immunoreactive bands were visualized by chemiluminescence (Amersham, Braunschweig, Germany). The antibodies used in this study were: Anti-caspase-3 (#200021; Stratagene, La Jolla, CA, USA), anti-p53 and anti-p21 (#OP43 and #OP64; Oncogene, Cambridge, MA, USA), and anti-FLIP (#343002; Calbiochem, San Diego, CA, USA). The antibodies were used at the concentrations recommended by the manufacturers.
Cell cycle analysis by FACS
HCT116 and HUVEC cells were incubated and treated as described in the ®gure legends. After the treatments, both oating cells in the medium and live cells in the plate were collected. Cycle TEST PLUS DNA TM reagent kit (Becton Dickinson and Co., San JoseÂ , CA, USA) was used to stain cells according to the manufacturer's instruction. The stained cells were analysed in a FACS sorter (Becton Dickinson and Co.). The percentage of apoptotic cells containing a sub-G, DNA content was quantitated using the CellQuest program. The percentage of live cells in each phase of cell cycle was quantitated using the ModFit LT program.
